Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Pharmacokinetics of YM178
Interventions: mirabegron, rifampin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Participants
Interventions: BMS-986278 Tablet, Esomeprazole, BMS-986278 suspension; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin + metformin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Gout, Hyperuricemia
Interventions: Xanthine Oxidase Inhibitor; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Asthma
Interventions: Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more

Conditions: Medical Oncology
Interventions: Anetumab ravtansine (BAY94-9343), Itraconazole; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more

Conditions: Purpura, Thrombocytopenic, Idiopathic
Interventions: Eltrombopag, Cyclosporine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
Interventions: Envarsus, IR Tacrolimus; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 60 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Cardiotoxicity, Cardiovascular Diseases
Interventions: High Intensity Interval Exercise, Moderate Intensity Walking; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy Adults
Interventions: Prifetrastat; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: Tbo-filgrastim; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 9
States / cities: Duarte, California • La Jolla, California • Beech Grove, Indiana + 6 more

Conditions: Healthy
Interventions: Rosuvastatin, Clopidogrel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Perimenopausal Disorder, Depression
Interventions: Bazedoxifene/Conjugated Estrogen; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 44 Years to 55 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Skin and Soft Tissue Infections, Abscess
Interventions: Standard of Care (SoC), Irrisept Delivery System; Device
Lead sponsor: Irrimax Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: COVID-19-Induced Parosmia
Interventions: Stellate Ganglion Block, Placebo Sham Injection; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity, Overweight
Interventions: Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 34
States / cities: Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more

Conditions: COVID-19
Interventions: EDP-235, Itraconazole, Carbamazepine, Quinidine; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cushing Syndrome, Neoplasms
Interventions: Dabigatran Etexilate, Relacorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Drug Interaction Potentiation, Healthy
Interventions: Mifepristone 300 MG, Itraconazole 100 MG; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • San Diego, California + 2 more

Conditions: Cognitive Change, Inflammation, Immune Response
Interventions: Q CAN PLUS, Placebo; Dietary Supplement
Lead sponsor: Loma Linda University; Other
Eligibility: 65 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions: Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy; Dietary Supplement · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiac Toxicity, Early-stage Breast Cancer
Interventions: Lipitor 40mg Tablet; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more

Conditions: Alzheimer's Disease
Interventions: Simvastatin, L-Arginine, Tetrahydrobiopterin; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 55 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Worcester, Massachusetts

Search by objective public record fields.

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants

Drug Interaction Study of Clopidogrel and Rosuvastatin

Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"

The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

Stellate Ganglion Block for COVID-induced Parosmia

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

Effect of a Fermented Soy Product on Cognition, Immune Status and Vaccine

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Endothelial Facilitation in Alzheimer's Disease